{
    "name": "nicotine intranasal",
    "comment": "Rx",
    "other_names": [
        "Nicotrol NS"
    ],
    "classes": [
        "Smoking Cessation Aids"
    ],
    "source": "https://reference.medscape.com/drug/nicotrol-ns-nicotine-intranasal-999837",
    "pregnancy": {
        "common": [
            "Pregnancy Category: D",
            "Lactation: Distributed in breast milk; milk to plasma ratio is 2.9"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Distributed in breast milk; milk to plasma ratio is 2.9"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Irritating to nasal mucosa",
                "Not studied in reactive airway disease; may cause bronchospasm",
                "Caution with hypertension, cardiovascular, or peripheral vascular disease",
                "Caution with hyperthyroidism, pheochromocytoma, or insulin-dependent diabetes, since nicotine causes the release of catecholamines by the adrenal medulla",
                "Delays healing of peptic ulcer disease"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "cabotegravir",
            "description": {
                "common": "nicotine intranasal will decrease the level or effect of cabotegravir by  increasing metabolism. Contraindicated. Cabotegravir is metabolized by UGT1A1 and UGT1A9. Strong UGT1A1 or UGT1A9 inducers decrease cabotegravir systemic exposure, thereby increasing potential for loss of virologic response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "adenosine",
            "description": {
                "common": "nicotine intranasal increases effects of adenosine by unknown mechanism. Use Caution/Monitor. Adenosine associated tachycardia and chest pain."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine increases levels of nicotine intranasal by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esketamine intranasal",
            "description": {
                "common": "esketamine intranasal, nicotine intranasal.\nEither increases toxicity of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Closely monitor blood pressure with concomitant use of esketamine nasal with stimulants. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "green tea",
            "description": {
                "common": "green tea, nicotine intranasal. Other (see comment). Use Caution/Monitor. \nComment: Green tea may include caffeine. Caffeine is a CNS-stimulant and additive effects may be seen when coadministered with other CNS stimulants. Caffeine should be avoided or used cautiously."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naphazoline",
            "description": {
                "common": "naphazoline decreases levels of nicotine intranasal by Other (see comment). Use Caution/Monitor. \nComment: Nasal vasoconstrictors prolong the time to peak concentrations by ~40% and decreases peak concentration by ~20%."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxymetholone",
            "description": {
                "common": "oxymetholone decreases levels of nicotine intranasal by Other (see comment). Use Caution/Monitor. \nComment: Nasal vasoconstrictors prolong the time to peak concentrations by ~40% and decreases peak concentration by ~20%."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenylephrine nasal",
            "description": {
                "common": "phenylephrine nasal decreases levels of nicotine intranasal by Other (see comment). Use Caution/Monitor. \nComment: Nasal vasoconstrictors prolong the time to peak concentrations by ~40% and decreases peak concentration by ~20%."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propylhexedrine",
            "description": {
                "common": "propylhexedrine decreases levels of nicotine intranasal by Other (see comment). Use Caution/Monitor. \nComment: Nasal vasoconstrictors prolong the time to peak concentrations by ~40% and decreases peak concentration by ~20%."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "solriamfetol",
            "description": {
                "common": "nicotine intranasal and solriamfetol both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "varenicline",
            "description": {
                "common": "varenicline increases toxicity of nicotine intranasal by Other (see comment). Use Caution/Monitor. \nComment: Varenicline is a partial agonist at the nicotinic Ach receptor; concomitant use with nicotine replacement therapy may increase adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "xylometazoline",
            "description": {
                "common": "xylometazoline decreases levels of nicotine intranasal by Other (see comment). Use Caution/Monitor. \nComment: Nasal vasoconstrictors prolong the time to peak concentrations by ~40% and decreases peak concentration by ~20%."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bupropion",
            "description": {
                "common": "bupropion, nicotine intranasal.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypertension."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dihydroergotamine",
            "description": {
                "common": "dihydroergotamine, nicotine intranasal. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive vasospasm."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dihydroergotamine intranasal",
            "description": {
                "common": "dihydroergotamine intranasal, nicotine intranasal. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive vasospasm."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "niacin",
            "description": {
                "common": "nicotine intranasal increases effects of niacin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rose hips",
            "description": {
                "common": "nicotine intranasal decreases levels of rose hips by increasing elimination. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Local irritation",
            "percent": "94"
        },
        {
            "name": "Anxiety",
            "percent": null
        },
        {
            "name": "Irritability",
            "percent": null
        },
        {
            "name": "Restlessness",
            "percent": null
        },
        {
            "name": "Cravings",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Impaired concentration",
            "percent": null
        },
        {
            "name": "Weight increase",
            "percent": null
        },
        {
            "name": "Emotional lability",
            "percent": null
        },
        {
            "name": "Somnolence and fatigue",
            "percent": null
        },
        {
            "name": "Increased sweating",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Confusion",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "Apathy",
            "percent": null
        },
        {
            "name": "Tremor",
            "percent": null
        },
        {
            "name": "Increased appetite",
            "percent": null
        },
        {
            "name": "Incoordination",
            "percent": null
        },
        {
            "name": "Increased dreaming",
            "percent": null
        }
    ]
}